Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials

References

• . Burrows N, Parekh S, Li Y, Geiss L. Prevalence of self-reported cardiovascular disease among persons aged a 35 years with diabetes— United States, 1997–2005. MMWR Weekly. 2007;56(43):1129–1132
   PubMedGoogle Scholar
• . Jurado J, Ybarra J, Solanas P, . Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Pract. 2009;21(3):140–148
   PubMed Web of Science ®Google Scholar
• . US Department of Health and Human Services; Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed March 24, 2013
   Google Scholar
• . Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med. 2001;249(3):225–235
   PubMed Web of Science ®Google Scholar
• . Milicevic Z, Raz I, Beattie SD, . Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care. 2008;31( suppl 2):S155–S160
   PubMedGoogle Scholar
• . Gerstein HC, Miller ME, Byington RP, ; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• . Patel A, MacMahon S, Chalmers J, . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T, . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Ray KK, Seshasai SR, Wijesuriya S, . Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, ; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36( suppl 1):S11–S66
   PubMed Web of Science ®Google Scholar
• . Glucotrol® (glipizide tablets) [package insert]. New York, NY: Pfizer Inc; 2010
   Google Scholar
• . Micronase® (glyburide tablets) [package insert]. New York, NY: Pfizer Inc; 2010
   Google Scholar
• . ACTOS (pioglitazone hydrochloride) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2012
   Google Scholar
• . AVANDIA® (rosiglitazone maleate) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011
   Google Scholar
• . Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454–1470
   PubMed Web of Science ®Google Scholar
• . Onglyza® (saxagliptin) [package insert]. Princeton, NJ: Bristol-Myers Squibb; Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011
   Google Scholar
• . Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–2411
   PubMed Web of Science ®Google Scholar
• . Frederich R, McNeill R, Berglind N, Fleming D, Chen R. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012;4(1):36
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Hissa MN, Garber AJ, . The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–1655
   PubMed Web of Science ®Google Scholar
• . Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–1406
   PubMed Web of Science ®Google Scholar
• . Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94(12):4810–4819
   PubMed Web of Science ®Google Scholar
• . Frederich R, Alexander JH, Fiedorek FT, . A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27
   PubMed Web of Science ®Google Scholar
• . Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab. 2012;14(4):365–371
   PubMed Web of Science ®Google Scholar
• . Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619–1631
   PubMed Web of Science ®Google Scholar
• . Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–622
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Karl DM. Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care. 2012;35(10):2100–2107
   PubMed Web of Science ®Google Scholar
• . Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia. 2009;52(7):1219–1226
   PubMed Web of Science ®Google Scholar
• . Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393
   PubMed Web of Science ®Google Scholar
• . Pantalone KM, Kattan MW, Yu C, . Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012;14(9):803–809
   PubMed Web of Science ®Google Scholar
• . Pantalone KM, Kattan MW, Yu C, . The risk of overall mortality in patients with type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis. Diabet Med. 2012;29(8):1029–1035
   PubMed Web of Science ®Google Scholar
• . Meinert CL, Knatternd GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19( suppl): 789–830
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35( suppl 1):S11–S63
   PubMed Web of Science ®Google Scholar
• . Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med. 2007;24(5):541–549
   PubMed Web of Science ®Google Scholar
• . Colhoun HM, Betteridge DJ, Durrington PN, . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia. 2009;52(1):50–59
   PubMed Web of Science ®Google Scholar
• . Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes-the CORALL study. Diabet Med. 2012;29(5):628–631
   PubMed Web of Science ®Google Scholar
• . Sattar N, Preiss D, Murray HM, . Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Danielson E, Fonseca FA, . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207
   PubMed Web of Science ®Google Scholar
• . Laakso M. Diabetes as a ‘cardiovascular disease equivalent’: implications for treatment. Nat. Clin Pract Cardiovasc. Med. 2008;5(11):682–683
   PubMedGoogle Scholar
• . Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011;55(1–3):10–16
   PubMed Web of Science ®Google Scholar
• . Ban K, Hui S, Drucker DJ, Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens. 2009;3(4):245–259
   PubMed Web of Science ®Google Scholar
• . Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res. 2012;9(2):109–116
   PubMed Web of Science ®Google Scholar
• . Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187–215
   PubMed Web of Science ®Google Scholar
• . Scirica BM, Bhatt DL, Braunwald E, . The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011;162(5):818–825.e816
   PubMed Web of Science ®Google Scholar